Management of the transplant recipient with chronic hepatitis C

Area of Science:

• Hepatology
• Transplant Surgery
• Virology

Background:

• Hepatitis C virus (HCV) infection impacts over one-third of US liver transplant candidates.
• HCV recurrence post-liver transplant leads to faster graft failure and reduced patient survival.
• Existing treatments (peginterferon, ribavirin, first-generation protease inhibitors) have limitations including poor response rates, drug interactions, and severe side effects.

Purpose of the Study:

• To review the challenges of HCV recurrence after liver transplantation.
• To discuss the limitations of current HCV treatment regimens.
• To highlight the potential of novel antiviral therapies for improving outcomes in liver transplant recipients.

Main Methods:

• Literature review of studies on HCV recurrence after liver transplantation.
• Analysis of current and emerging HCV treatment strategies.
• Evaluation of treatment efficacy, safety, and patient survival data.

Main Results:

• HCV recurrence remains a significant complication following liver transplantation.
• Current treatment regimens demonstrate suboptimal efficacy and tolerability.
• Emerging direct-acting antiviral (DAA) therapies show promise for enhanced viral response and improved safety profiles.

Conclusions:

• Novel HCV therapies are expected to significantly improve post-transplant outcomes.
• These new treatments aim to reduce treatment duration, minimize drug interactions, and enhance patient survival.
• Advancements in HCV drug development offer a more optimistic future for liver transplant recipients.